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Abstract
Background: Statins are used to treat and prevent cardiovas-
cular diseases (CVDs) by reducing the total serum choles-
terol concentration. Unfortunately, dose-related side effects 
and sub-optimal response, attributed to non-adherence 
amongst others, were described. Therefore, a fast and sen-
sitive liquid chromatography-high-resolution tandem mass 
spectrometry (LC-HRMS/MS) method for adherence testing 
and therapeutic drug monitoring of all currently marketed 
statins and their active metabolites in human blood plasma 
should be developed, validated and tested for applicability.
Methods: Atorvastatin, fluvastatin, lovastatin, pitavasta-
tin, pravastatin, rosuvastatin, and simvastatin, as well as 
ortho- and para-hydroxy-atorvastatin, lovastatin hydroxy 
acid and simvastatin hydroxy acid were included and 
several internal standards (IS) tested. Validation was per-
formed according to the guideline of the European Medi-
cines Agency including selectivity, carry-over, accuracy, 
precision, matrix effects, dilution integrity and analyte 
stability. Finally, applicability was tested using 14 patient 
samples submitted for regular toxicological analysis.
Results: Due to an analytical interference of 
 atorvastatin-d5, diazepam-d5 and pentobarbital-d5  were 
chosen as IS for positive and negative ionization mode, 
respectively. All  statins and metabolites fulfilled the vali-
dation acceptance criteria except for fluvastatin, which 
could not be quantified reliably and reproducibly, most 
probably due to instability. Analyses of human plasma 
samples revealed concentrations of statins and metabolites 
below the reference plasma concentrations in the case of 
eight patients. However, nothing was known concerning 
patients’ adherence and time between intake and sampling.
Conclusions: An LC-HRMS/MS method for identification 
and quantification of atorvastatin, lovastatin, pitavasta-
tin, pravastatin, rosuvastatin, simvastatin and four active 
metabolites was successfully developed and applicability 
demonstrated.
Keywords: adherence monitoring; cardiovascular dis-
eases; HMG-CoA reductase inhibitors; statins; TDM.
Introduction
Cardiovascular diseases (CVDs) are the most common 
cause of death worldwide [1]. Their incidence can be 
directly correlated to elevated low-density lipoprotein 
cholesterol (LDL-C) concentrations in blood [2]. Statins, 
inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase, are the most important cholesterol-lowering 
agents, which were also shown to have pleiotropic effects 
such as improved endothelial function, enhanced stabil-
ity of atherosclerotic plaques, decreased oxidative stress, 
and inhibition of thrombogenic responses [3, 4].
Standard statin regimens have been well-established 
to reduce the risk of occlusive vascular events and inter-
national guidelines recommended the use of statins for a 
broad range of patients to prevent and treat CVD [2, 5, 6]. 
However, dose-dependent side effects such as myalgia 
and liver toxicity were frequently described [7, 8].
Recently, Akyea et  al. reported a sub-optimal LDL-C 
response to statin therapy. The authors found that over half 
of patients started on statin therapy for primary prevention 
of CVD did not experience an optimal therapeutic reduction 
of their LDL-C levels 24 months after therapy initiation [9]. 
Individual biological and genetic variability, but also vari-
ations in adherence have been identified as main reasons 
*Corresponding author: Prof. Dr. Markus R. Meyer, Department 
of Experimental and Clinical Toxicology, Institute of Experimental 
and Clinical Pharmacology and Toxicology, Center for Molecular 
Signaling (PZMS), Saarland University, Kirrberger Str., Building 46, 
66421 Homburg, Germany, Phone: +49-6841-16-26430,  
Fax: +49-6841-16-26431, E-mail: markus.meyer@uks.eu 
Lea Wagmann and Achim T. Caspar: Department of Experimental 
and Clinical Toxicology, Institute of Experimental and Clinical 
Pharmacology and Toxicology, Center for Molecular Signaling 
(PZMS), Saarland University, Homburg, Germany
Selina Hemmer: Department of Experimental and Clinical 
Toxicology, Institute of Experimental and Clinical Pharmacology 
and Toxicology, Center for Molecular Signaling (PZMS), Saarland 
University, Homburg, Germany; and Department of Food Chemistry 
and Toxicology, Technical University Kaiserslautern, Kaiserslautern, 
Germany
Angemeldet | markus.meyer@uks.eu Autorenexemplar
Heruntergeladen am | 05.11.19 11:38
2      Wagmann et al.: Quantification of statins in blood plasma
[10, 11]. Both, the patients’ non-adherence and the dose-
dependent side effects underline the importance of meas-
uring blood plasma concentrations of statins [7, 8]. Several 
methods for quantification of often one single statin were 
published in the past but a comprehensive method cover-
ing all relevant compounds is still missing [4, 12–24].
A liquid chromatography (LC)-high-resolution tandem 
mass spectrometry (HRMS/MS) method for identifica-
tion and quantification of all currently marketed statins 
( atorvastatin, fluvastatin, lovastatin, pitavastatin, pravas-
tatin, rosuvastatin, simvastatin) in human blood plasma 
should be developed and validated [8]. Furthermore, 
the active metabolites ortho (o)-hydroxy-atorvastatin, 
para (p)-hydroxy-atorvastatin, lovastatin hydroxy acid 
and simvastatin hydroxy acid were included. Chemical 
structures of the parent compounds and the metabolites 
can be found in Figure 1. Standard daily doses, elimina-
tion half-life, and reference plasma concentrations are 
summarized in Table 1 [25]. The developed method should 
be applicable for adherence monitoring as well as thera-
peutic drug monitoring, demonstrated by analyses of 
authentic patient blood plasma samples.
Materials and methods
Chemicals
Simvastatin hydroxy acid ammonium salt, pitavasta-
tin hemicalcium salt, p-hydroxy-atorvastatin calcium salt, 
Figure 1: Chemical structures of the investigated seven statins and their four active metabolites. 
M, metabolite.
Table 1: Standard daily dose, elimination half-life, and reference plasma concentration of seven statins according to [25].
Analyte   Standard daily dose, mg  Elimination half-life, h  Reference plasma concentration, ng/mL
Atorvastatin   10–80  11–24  7–252  (Atorvastatin),
      13–43  (o-Hydroxy-atorvastatin),
      1–5  (p-Hydroxy-atorvastatin)
Fluvastatin   20–80  1–3  54–438 
Lovastatin   10–80  2–3  3–7  (Lovastatin),
      3–18  (Lovastatin hydroxy acid)
Pitavastatin   1–4  5–13  31–81 
Pravastatin   10–40  2–3  4–69 
Rosuvastatin   5–40  12–32  8–20 
Simvastatin   5–80  2–4  3–6  (Simvastatin),
      1–9  (Simvastatin hydroxy acid)
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o-hydroxy-atorvastatin calcium salt, and atorvastatin-d5 calcium 
salt (internal standard, IS) were purchased from Alsachim (Shi-
madzu Group Company, France), rosuvastatin hemicalcium salt, 
ammonium formate, dimethylsulfoxid (DMSO), and formic acid 
from Sigma–Aldrich (Taufkirchen, Germany), lovastatin, lovasta-
tin hydroxy acid, simvastatin and atorvastatin from LGC Standards 
(Wesel, Germany), pravastatin from Daiichi-Sankyo Europe GmbH 
(Munich, Germany), fluvastatin from Sandoz Pharma AG (Basel, 
Switzerland), acetonitrile (ACN), diethyl ether, ethyl acetate and 
methanol from VWR International GmbH (Darmstadt, Germany), 
and diazepam-d5 (IS) and pentobarbital-d5 (IS) from LGC Stand-
ards (Wesel, Germany). Drug free pooled human blank plasma was 
obtained from a local blood bank.
Preparation of stock and working solutions
Stock solutions (1 g/L) of each compound were prepared separately 
in DMSO. The working solution containing all substances (10 mg/L 
each) was prepared by dilution of stock solutions with ACN. Solu-
tions were stored at −20 °C.
Sample preparation
Based on a previously published extraction procedure [21], 100 μL 
blood plasma, 10 μL IS mix (100 ng/mL atorvastatin-d5 or 250 ng/mL 
diazepam-d5 and 1000 ng/mL pentobarbital-d5 in methanol), and 
10 μL formic acid (100%) were mixed in an 1.5  mL reaction tube. 
One milliliter of a diethyl ether-ethyl acetate mixture (1:1, v/v) was 
added. Afterwards, the mixture was shaken (10 min) and centrifuged 
(2 min, 18,407 × g). Eight hundred μL of the clear organic layer were 
evaporated to dryness at 45 °C under a gentle stream of nitrogen, 
reconstituted with 40 μL of a mixture of eluents A and B (1:1, v/v, see 
LC-HRMS/MS conditions), and analyzed by the LC-HRMS/MS system 
described below.
LC-HRMS/MS apparatus
Samples were analyzed using a Thermo Fisher Scientific (TF, 
Dreieich, Germany) Dionex UltiMate 3000 Rapid Separation LC sys-
tem consisting of a degasser, a quaternary pump, and a HTC PAL 
autosampler (CTC Analytics AG, Zwingen, Switzerland), coupled to 
a TF Q-Exactive mass spectrometer (TF, Dreieich, Germany) with a 
heated electrospray ionization (HESI)-II source. Gradient elution was 
performed on a TF Hypersil GOLD C18 column (1.9 μm, 2.1 × 100 mm) 
at 40 °C. Eluent A (millipore water containing 1% ACN, 0.1% formic 
acid, and 2 mM ammonium formate) and eluent B (ACN containing 
1% mL Millipore water, 0.1% mL formic acid, and 2 mM ammonium 
formate) were used as mobile phases. The gradient was programmed 
as follows: 0–3 min from 35% to 50% eluent B, 3–5 min hold 50% elu-
ent B, 5–8 min to 80% eluent B, 8–9 min hold 80% eluent B, 9.01–11 min 
hold 35% eluent B, with a constant flow rate of 0.7 mL/min. The injec-
tion volume was set to 5.0 μL.
The HESI-II source conditions were as follows: ionization mode, 
pos/neg switching; sheath gas flow rate, 60.0 arbitrary units (AU); 
auxiliary gas flow rate, 10.0 AU; spray gas voltage 3.0  kV (positive 
polarity) and −4.0 kV (negative polarity); auxiliary gas heater tem-
perature, 320 °C; ion transfer capillary temperature, 320 °C; and 
S-lens RF level, 60.0. Full scan analysis (scan range mass-to-charge 
ratio value, m/z, 130–1000) was used to determine the retention 
times of all analytes. All other analyses were performed using tar-
geted selected ion monitoring (t-SIM) mode with an inclusion list 
containing the masses of interest and expected retention times. The 
settings for t-SIM were as follows: resolution 35,000; microscans 1; 
automatic gain control target 5e4; maximum injection time 250 ms; 
isolation window 1.0 m/z. Xcalibur Qual Browser software version 
2.2 was used for data evaluation.
Method validation
Method validation was performed according to the Guideline on Bio-
analytical Method Validation published by the European Medicines 
Agency [26]. For data evaluation, peak area ratios of analyte (accu-
rate masses are given in Table 2) and IS (atorvastatin-d5 for posi-
tive and negative or diazepam-d5 for positive and pentobarbital-d5 
for negative ionization mode) were used. Statistical evaluation was 
performed using Microsoft Excel for Mac Version 16.18 (Microsoft, 
Redmond, WI, USA) and GraphPad Prism 5.00 (GraphPad Software, 
La Jolla, CA, USA).
To test selectivity, 12  human plasma samples from different 
donors were tested for peaks interfering with the detection of the ana-
lytes or IS in t-SIM mode. These samples did not contain statins, but 
other frequently prescribed drugs such as antidepressants (e.g. mir-
tazapine, sertraline), neuroleptics (e.g. pipamperone), sedatives (e.g. 
midazolam), and cardiovascular drugs (e.g. metoprolol, torasemide), 
or other substances for example, ethanol, nicotine, and tetrahydro-
cannabinol (THC). For carry-over testing, a blank sample was injected 
after analysis of a high concentration sample (all analytes 100 ng/mL).
Table 2: Precursor ion masses, used ionization modes (+, positive; 
−, negative), retention order, and retention times of the statins, 
their active metabolites, and internal standards (marked as IS).







Atorvastatin   +559.2603  9  4.5
Atorvastatin-M (o-hydroxy)   −573.2406  7  3.9
Atorvastatin-M (p-hydroxy)   −573.2406  5  2.1
Diazepam-d5 (IS)   +290.1103  6  2.6
Fluvastatin   +412.1919  8  4.3
Lovastatin   +405.2634  12  6.6
Lovastatin-M   −421.2596  10  5.1
Pentobarbital-d5 (IS)   −230.1558  2  1.1
Pitavastatin   +422.1762  3  1.3
Pravastatin   −423.2388  1  0.9 (and 
artifact at 
1.2 min)
Rosuvastatin   +482.1756  4  1.9
Simvastatin   +419.2792  13  7.6
Simvastatin-M   −435.2752  11  6.0
M, metabolite.
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Two calibration ranges were defined, both consisting of six cali-
bration points. Calibrators were prepared by spiking blank plasma 
with working solution (final plasma concentrations see Table 3) and 
were extracted as described in the section “sample preparation”. 
The lower limit of quantification (LLOQ) was defined to be 1 ng/mL 
for all analytes and the upper limit of quantification (ULOQ) 20 
or 100  ng/mL depending on the analyte. Additionally, blank sam-
ple (blank plasma without analytes and IS) and zero sample (blank 
plasma without analytes, but with IS) were extracted. For all calibra-
tion curves, a linear calibration model with different weighting fac-
tors (equal, 1/x, or 1/x2) was tested by back calculating calibration 
standards. Back calculated concentrations should be within ±15% of 
the nominal value (±20% for LLOQ).
Accuracy and precision of the quantification results were deter-
mined using four different levels as quality controls (QC), listed in 
Table 3: LLOQ QC, low QC, medium QC, and high QC. The within-run 
accuracy and precision were determined by analyzing five samples 
per level in a single run. The between-run accuracy and precision 
were determined by analyzing five samples per level in three runs 
analyzed on three different days. For positive assessment of accuracy, 
the mean concentration should be within ±15% of the nominal val-
ues for the QC samples, except for the LLOQ, which should be within 
±20% of the nominal value. For positive assessment of precision, the 
coefficient of variation (CV) value should not exceed ±15% for the QC 
samples, except for the LLOQ, which should not exceed ±20%.
Dilution integrity was determined by spiking five blank blood 
plasma samples to final plasma concentrations 5-times above the 
high QC (90 or 425 ng/mL, respectively, depending on the analyte). 
Afterwards, they were diluted with blank blood plasma (1:10, v/v, 
final plasma concentration 9 or 42.5 ng/mL, respectively), analyzed, 
and accuracy and precision determined.
Matrix effects should be investigated using the matrix factor (MF) of 
each analyte and IS determined by calculating the ratio of the peak area 
in the presence of matrix (measured by analyzing blank matrix spiked 
after extraction with analyte) to the peak area in absence of matrix (pure 
solution of the analyte) in six lots of matrix. Determined MFs were after-
wards used for calculation of the IS- normalized MF by dividing the MF 
of the analyte by the MF of the IS. This should be done at a low and a 
high level of concentration and the CV of the IS-normalized MF calcu-
lated from the six lots of matrix should not be greater than ±15%.
Stability of analytes should be determined during storage before 
and after sample preparation at two concentration levels (low and 
high QC, n = 3, respectively). QC samples were analyzed immediately 
after preparation and after the evaluated storage conditions using a 
freshly prepared calibration curve. Afterwards, the obtained concen-
trations were compared to the nominal concentrations. The mean 
concentration at each level should be within ±15% of the nominal 
concentration. For short-term stability of the analytes in the matrix, 
blank blood plasma was spiked and stored for 20 h at room tempera-
ture or +4 °C. For long term stability of the analytes in the matrix, 
storage took 3  weeks at −20 °C. Stability of processed samples in 
the autosampler was evaluated by reanalyzing processed samples 
stored for 20 h in the autosampler (+10 °C). For freeze and thaw sta-
bility, spiked plasma samples were stored in a freezer at −20 °C for 
20 h, thawed at room temperature, extracted, analyzed (freeze/thaw 
cycle  1), and the remaining spiked plasma was refrozen. Overall, 
three freeze/thaw cycles were conducted.
Application to authentic samples
Human blood plasma samples of 14 different individuals with pre-
scribed statin therapy were used for applicability testing. Samples 
were submitted to the authors’ laboratory for regular toxicologi-
cal screening purposes. Medication plans were thus also provided. 
All specimens used for applicability testing were submitted to the 
authors’ laboratory for regular toxicological screening purposes 
including statin determination.
Results
Method development and validation
As shown in Figure 2, chromatographic separation was 
performed within 8 min. Identification of a compound was 
based on two criteria. First, the accurate mass of the proto-
nated or deprotonated precursor ion and second, the corre-
sponding retention time in t-SIM mode. Peak area ratios of 
analyte and IS were used for quantification. If pravastatin 
Table 3: Final plasma concentrations (ng/mL) of the analytes in calibrator samples (Cal 1–6) and quality control samples (QC) as well as 
weighting factors used in a linear calibration model. 
Analyte   Cal 1 (=LLOQ)  Cal 2  Cal 3  Cal 4  Cal 5  Cal 6  Low QC  Medium QC  High QC  Weighting
Atorvastatin   1  20  40  60  80  100  3  50  85  1/x2
Atorvastatin-M (o-hydroxy)  1  20  40  60  80  100  3  50  85  1/x2
Atorvastatin-M (p-hydroxy)  1  4  8  12  16  20  3  10  18  Equal
Fluvastatin   1  20  40  60  80  100  3  50  85  –
Lovastatin   1  4  8  12  16  20  3  10  18  Equal
Lovastatin-M   1  4  8  12  16  20  3  10  18  1/x
Pitavastatin   1  20  40  60  80  100  3  50  85  1/x2
Pravastatin   1  20  40  60  80  100  3  50  85  1/x
Rosuvastatin   1  20  40  60  80  100  3  50  85  1/x2
Simvastatin   1  4  8  12  16  20  3  10  18  1/x2
Simvastatin-M   1  4  8  12  16  20  3  10  18  1/x
M, metabolite.
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was present, an additional peak with the same m/z as 
pravastatin (m/z 423.2388 in negative ionization mode) 
was detected in some analytical runs (see Figure 2). The 
second peak eluted later (1.2 min) and had a lower abun-
dance and smaller peak area in comparison to pravastatin 
(0.9 min). The second peak was most probably a pravas-
tatin isomer formed during sample preparation and was 
quantified together with the pravastatin if present [27]. 
During method validation, atorvastatin-d5 (final plasma 
concentration 10 ng/mL) provided a lower peak area in 
zero samples containing only the IS, than in samples con-
taining additional atorvastatin. Therefore, the influence of 
the co-eluting analytes atorvastatin and atorvastatin-d5 
on each other’s signal intensity was tested by comparing 
their peak areas in combination (both 100  ng/mL) to 
those after single analysis (n = 3, respectively). Co-eluting 
atorvastatin led to an ion enhancement >50% of the atorv-
astatin-d5 peak area. The signal intensities of diazepam-d5 
and pentobarbital-d5, used as alternative to atorvastatin-
d5, were not influenced by the analytes.
Twelve blank blood plasma samples obtained from 
individual sources were analyzed and evaluated for inter-
ferences. No interfering signals or false positive results 
were observed during analysis of the 12  selectivity test 
samples. No analyte carry-over was detectable in the 
blank sample injected after analysis of the high concen-
tration sample containing an analyte concentration of 100 
ng/mL, respectively. For all analytes except of fluvastatin 
a linear calibration model could be fitted using the weight-
ing factors given in Table 3. In case of fluvastatin, back-
calculation of the calibrator concentrations exceeded the 
limits (±15% and ±20% for LLOQ of the nominal value) 
using a linear calibration model and the aforementioned 
weighting factors. Therefore, fluvastatin was not consid-
ered further for validation due to reasons discussed later.
Within-run and between-run accuracy were found 
to be acceptable with mean concentrations within ±15% 
of the nominal values for the low, medium, and high 
QC samples (0–15%) and within ±20% for the LLOQ QC 
samples (2–20%) for all analytes. Within-run and between-
run precision were expressed as the CV and also found to 
be acceptable with CV values within ±15% for the low, 
medium, and high QC samples (3–15%) and within ±20% 
for the LLOQ QC samples (2–20%) for all analytes. After 
dilution of samples spiked above the ULOQ, determined 
concentrations were also found to be accurate (1–14% var-
iation) and precise (CVs of 4–14%) for all analytes.
Determined IS-normalized MFs and CVs of all com-
pounds are given in Table 4. The presence of matrix had 
the highest influence on pravastatin and p-hydroxy-ator-
vastatin signals at low concentrations (−75%, and +72%, 
respectively), as well as at high concentrations (–41% and 
+75%, respectively). However, these effects were found to 
be reproducible with CVs within 15%. This was also true 
for all other analytes at both concentration levels (CVs of 
6–15%).
Results for short- and long-term stability testing of 
the analytes in the matrix are given in Table 5. Lovastatin 
and simvastatin were unstable in matrix if stored for 20 h 
at room temperature (22 °C). After storage, the concen-
tration of lovastatin decreased by more than 90% at low 
and high concentration levels and of simvastatin by more 
than 70%, while the concentrations of their hydroxy acid 
metabolites increased in a comparable extent. This was 
not observed after storage for 20 h at +4 °C or for 3 weeks 
at −20 °C. Mean concentrations in low and high QC were 
Figure 2: Reconstructed chromatogram of the m/z of all analytes in blood plasma (100 ng/mL) measured in t-SIM mode.
1, Pravastatin; 2, pentobarbital-d5 (internal standard); 3, pitavastatin; 4, rosuvastatin; 5, p-hydroxy atorvastatin; 6, diazepam-d5 (internal 
standard); 7, o-hydroxy atorvastatin; 8, fluvastatin; 9, atorvastatin; 10, lovastatin hydroxy acid; 11, simvastatin hydroxy acid; 12, lovastatin; 
13, simvastatin.
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within ±15% of the nominal concentration for all other 
analytes.
After storage of processed samples in the autosampler 
for 20 h, mean concentrations of all analytes in low and 
high QC were within ±15% of the nominal concentration 
as given in Table 5. The same was true for the mean con-
centrations of all analytes in low and high QC after three 
freeze/thaw cycles of the matrix (only results of the third 
cycle given in Table 5).
Application to human plasma samples
The concentrations, which were determined in 14 plasma 
samples, are listed in Table 6.
Discussion
LC in combination with MS/MS is the technique of choice 
for the quantification of statins in biological matrices 
due to its sensitivity, selectivity, and simplicity [12]. The 
review articles by Nirogi et  al. and Patel and Kothari 
provide an overview on published statin bioanalysis 
[4, 12]. Multiple LC-MS/MS methods focusing on quanti-
fication of only one statin, sometimes plus metabolite(s), 
in human blood plasma were published recently [13–20]. 
Only a few numbers of methods including more than 
one statin were published in the past [21–24]. However, 
to the best of our knowledge, this is the first LC-HRMS/
MS method aiming to include all seven currently mar-
keted statins plus their active metabolites for adherence 
Table 5: Stability of analytes in matrix after short or long term storage or three freeze and thaw cycles (3FT) given as relative mean 
concentration ± coefficient of variation (CV) of low and high quality control (QC) samples (n = 3) determined before and after application 
of the following matrix storage conditions: 20 h at room temperature (RT), 20 h at +4 °C, and 3 weeks (w) at −20 °C, three freeze and thaw 








20 h, RT  20 h, +4 °C  3 w, −20 °C  3FT  AS 20 h, RT  20 h, +4 °C  3 w, −20 °C  3FT  AS
Atorvastatin   102 ± 9  110 ± 12  101 ± 7  108 ± 16  102 ± 6  114 ± 11  111 ± 12  112 ± 8  104 ± 15  99 ± 5
Atorvastatin-M (o-hydroxy)  97 ± 14  114 ± 12  112 ± 19  96 ± 16  107 ± 15  97 ± 11  111 ± 11  106 ± 14  90 ± 10  100 ± 7
Atorvastatin-M (p-hydroxy)  94 ± 5  105 ± 4  86 ± 10  109 ± 8  100 ± 12  100 ± 11  103 ± 11  86 ± 10  88 ± 10  95 ± 12
Lovastatin   2b ± 61  103 ± 5  99 ± 10  105 ± 20  97 ± 15  9b ± 69  92 ± 9  115 ± 13  114 ± 21  105 ± 13
Lovastatin-M   204b ± 40  110 ± 12  111 ± 7  109 ± 13  97 ± 15  269b ± 57  107 ± 7  101 ± 8  102 ± 16  105 ± 13
Pitavastatin   110 ± 8  102 ± 4  106 ± 10  111 ± 17  114 ± 8  112 ± 9  104 ± 7  113 ± 9  108 ± 10  115 ± 9
Pravastatina   115 ± 19  112 ± 23  100 ± 20  102 ± 11  105 ± 9  100 ± 21  97 ± 18  108 ± 18  91 ± 18  109 ± 9
Rosuvastatin   103 ± 6  114 ± 10  103 ± 6  109 ± 11  102 ± 6  111 ± 10  110 ± 11  104 ± 7  110 ± 9  99 ± 7
Simvastatin   21b ± 72  101 ± 10  104 ± 8  108 ± 21  102 ± 13  22b ± 63  93 ± 8  97 ± 13  107 ± 12  95 ± 8
Simvastatin-M   199b ± 38  111 ± 10  105 ± 12  114 ± 16  101 ± 19  199b ± 37  100 ± 7  112 ± 10  93 ± 18  97 ± 8
Stability of processed samples in the autosampler (AS, 20 h at +10 °C) is also given; M, metabolite. aSummarized peak areas of pravastatin 
and pravastatin artifact were used for quantification. bConcentration changes >15% are marked.
Table 4: Internal standard (IS)-normalized matrix factors (MF) of the analytes and coefficients of variation (CV) derived from measurements 
of six lots of matrix at a low (low QC) and a high level concentration (high QC, see Table 3). 
Analyte Low QC High QC
IS-normalized MF CV, % IS-normalized MF CV, %
Atorvastatin 1.70 ±15 1.28 ±14
Atorvastatin-M (o-hydroxy) 1.48 ±14 1.04 ±14
Atorvastatin-M (p-hydroxy) 1.72 ±14 1.75 ±15
Lovastatin 1.33 ±13 1.09 ±11
Lovastatin-M 0.94 ±13 0.99 ±6
Pitavastatin 0.95 ±9 0.96 ±10
Pravastatina 0.25 ±13 0.59 ±15
Rosuvastatin 0.92 ±14 0.90 ±6
Simvastatin 1.44 ±12 1.22 ±8
Simvastatin-M 0.91 ±13 0.99 ±6
aSummarized peak areas of pravastatin and pravastatin artifact were used for quantification. M, metabolite.
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monitoring, as well as therapeutic drug monitoring 
purposes.
Sample preparation by liquid-liquid extraction was 
based on the recommendation by Pilli et  al. [21] with 
minor modifications. Only 100 μL of blood plasma was 
mixed with diethyl ether and ethyl acetate instead of pure 
ethyl acetate to achieve a better separation of aqueous 
and organic phases. Chromatographic separation of all 
analytes was achieved within 8 min and a single analysis 
was performed in a total run time of 11 min. Such a quick 
sample preparation and short run time is expected to 
save resources and will facilitate the integration in daily 
routine work of toxicological laboratories. During analy-
sis of authentic samples, each analytical batch consisted 
of a blank sample, a zero sample, the calibration stand-
ards, three levels of QC samples (low, medium, high) in 
duplicate, and the authentic samples. In case of pravas-
tatin, two peaks were detected in some analytical runs 
(see Figure 2). Pravastatin was described to be prone to 
isomerization under acidic conditions [27]. Therefore, 
the second peak was expected to be a pravastatin artifact 
formed during sample preparation, which was not detect-
able during analysis of neat standard solution. Both peaks 
had to be used for correct quantification.
Atorvastatin-d5, the only commercially available deu-
terated statin at that time, was intended to be used as IS 
due to the structural similarity with the analytes and the 
possibility of analysis in positive and negative ioniza-
tion mode. However, co-eluting atorvastatin caused ion 
enhancement of the atorvastatin-d5. As the signal inten-
sities of diazepam-d5 and pentobarbital-d5  were not 
influenced by co-eluting compounds mainly due to suc-
cessful chromatographic separation (see Figure 2), they 
were used as IS for positive and negative ionization mode, 
respectively.
The developed method was considered as selective 
and no analyte carry-over was observed in the blank 
sample after injection of a high concentration sample. 
However, a washing run with blank plasma is recom-
mended if authentic samples with a concentration above 
100 ng/mL are analyzed.
Six statins and four active metabolites can be quan-
tified reliable and reproducible even after dilution. In 
summary, the present method allows plasma quantifi-
cation of p-hydroxy-atorvastatin, lovastatin, lovastatin 
hydroxy acid, simvastatin, and simvastatin hydroxy acid 
in the range of 1–20 ng/mL and of atorvastatin, o-hydroxy-
atorvastatin, pitavastatin, pravastatin and rosuvastatin 
in the range of 1–100 ng/mL. These ranges cover their 
reference plasma concentrations, which are summarized 
in Table 1. Only for atorvastatin, plasma concentrations 
above 100 ng/mL were described [25]. However, as dilu-
tion integrity was tested during validation, samples as 
high as 5-times above the high QC can be quantified reli-
ably after dilution with blank plasma.
Only fluvastatin failed the validation acceptance cri-
teria most probably due to its photosensitivity [28–30]. 
Nevertheless, light protection of blood plasma by wrap-
ping the flask with aluminum foil and use of amber glass 
vials did not improve the results. Fluvastatin was also 
described to be unstable under acidic conditions leading 
to lactonization [30].
Table 6: Results of applicability testing using 14 human samples. 
Sample 
no.
  Analyte   Daily 
dose, 
mg
  Measured plasma 
concentration, 
ng/mL
1   Atorvastatin   10  2
  Atorvastatin-M (o-hydroxy)     2
  Atorvastatin-M (p-hydroxy)     <1
2   Atorvastatin   10  <1
  Atorvastatin-M (o-hydroxy)     <1
  Atorvastatin-M (p-hydroxy)     n.d.
3   Atorvastatin   40  4
  Atorvastatin-M (o-hydroxy)     7
  Atorvastatin-M (p-hydroxy)     1
4   Atorvastatin   40  15
  Atorvastatin-M (o-hydroxy)     8
  Atorvastatin-M (p-hydroxy)     n.d.
5   Atorvastatin   20  <1
  Atorvastatin-M (o-hydroxy)     2
  Atorvastatin-M (p-hydroxy)     <1
6   Atorvastatin   20  <1
  Atorvastatin-M (o-hydroxy)     1
  Atorvastatin-M (p-hydroxy)     <1
7   Atorvastatin   20  <1
  Atorvastatin-M (o-hydroxy)     n.d.
  Atorvastatin-M (p-hydroxy)     <1
8   Pravastatina   40  18
9   Simvastatin   40  4
  Simvastatin-M     9
10   Simvastatin   10  3
  Simvastatin-M     1
11   Simvastatin   40  2
  Simvastatin-M     <1
12   Simvastatin   40  1
  Simvastatin-M     <1
13   Simvastatin   40  3
  Simvastatin-M     <1
14   Simvastatin   40  <1
  Simvastatin-M     <1
Prescribed statin, daily dose, and measures plasma concentration  
of parent compound and metabolites are given. n.d., not detected; 
M, metabolite. aSummarized peak areas of pravastatin and 
pravastatin artifact were used for quantification.
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Further evaluation of stability of all other analytes 
was carried out to ensure that the storage conditions used 
before and after sample preparation do not affect the ana-
lytes [26]. Conditions were the same that were expected 
to occur during analysis of authentic samples. Short-term 
stability testing clearly indicated, that plasma samples 
containing lovastatin or simvastatin should be stored 
at 4 °C until analysis. No stability issues after storage of 
plasma samples at −20 °C for 3 weeks and three freeze and 
thaw cycles were observed. Stability of processed samples 
in the autosampler for at least 20 h is of advantage if long 
analytical series are planned. However, the duration of an 
analytical run should not exceed 20 h, as stability of pro-
cessed samples in the autosampler can only be guaran-
teed for 20 h, based on these experiments.
Applicability of the current method was tested using 
14  human plasma samples of patients under statin 
therapy. Atorvastatin was prescribed to seven patients, 
simvastatin to six patients and pravastatin to one patient. 
These statins represent the most widely prescribed statins 
in Germany [31]. Unfortunately, samples containing the 
other statins were not available during the development 
of the study to further evaluate the applicability. Never-
theless, other statins may be predominately prescribed 
in other parts of the world and the current method is 
expected to be also applicable for their plasma quanti-
fication. It was remarkable that most of the determined 
concentrations (in the case of eight patients for parent 
compound and metabolite/metabolites and three patients 
only for metabolites) were below the reference plasma 
concentrations (see Table 1) [25]. However, it should be 
considered that the reference plasma concentrations were 
peak concentrations.
In the case of the authentic samples analyzed within 
the current study, sampling was not expected to be per-
formed at the time of peak concentration, as intake was 
prescribed once daily in the evening and sampling was 
usually performed in the morning. Comparably low plasma 
concentrations were determined in previous studies [14, 
24, 32]. Nirogi et al. described plasma  concentrations of 
atorvastatin and its metabolites below 1 ng/mL 3 h after 
the administration of an oral single dose of 10 mg of ator-
vastatin [14], while Polagani et al. reported atorvastatin 
plasma concentrations below 10 ng/mL approximately 
10 h after administration of 40 mg [32]. The short elimina-
tion half-lives of pravastatin and simvastatin (see Table 
1) should also be considered. However, the exact time 
between intake and sampling was not documented, as 
well as storage conditions before arrival at the labora-
tory. Furthermore, nothing was known about the adher-
ence of those patients. For future application of the 
current method, sample storage at +4 °C until  analysis is 
recommended.
Conclusions
An LC-HRMS/MS method for simultaneous quantification 
of six statins and four active metabolites was successfully 
developed and validated. Only 100 μL of human plasma 
was needed and a quick and easy sample preparation was 
followed by fast chromatographic separation. Applicabil-
ity was demonstrated by analysis of 14  human plasma 
samples. These samples contained the three most widely 
prescribed statins in Germany plus three active metabo-
lites. Determined plasma concentrations were below the 
reference peak plasma concentrations most probably due 
to elevated time span between sampling and intake. In the 
case of application of the current method for therapeutic 
drug monitoring or adherence testing time between intake 
and sampling has to be documented carefully and sam-
pling is recommended to be performed at the time point of 
the maximum plasma concentration.
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